1. Home
  2. MYGN vs VVX Comparison

MYGN vs VVX Comparison

Compare MYGN & VVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$6.58

Market Cap

625.5M

Sector

Health Care

ML Signal

HOLD

Logo V2X Inc.

VVX

V2X Inc.

HOLD

Current Price

$53.71

Market Cap

1.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYGN
VVX
Founded
1991
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Diversified Commercial Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
625.5M
1.7B
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
MYGN
VVX
Price
$6.58
$53.71
Analyst Decision
Buy
Buy
Analyst Count
12
10
Target Price
$11.82
$62.60
AVG Volume (30 Days)
1.1M
369.5K
Earning Date
11-03-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
791.53
EPS
N/A
2.51
Revenue
$825,300,000.00
$4,419,142,000.00
Revenue This Year
$0.10
$4.42
Revenue Next Year
$5.28
$5.45
P/E Ratio
N/A
$21.32
Revenue Growth
0.21
5.10
52 Week Low
$3.76
$41.08
52 Week High
$15.47
$63.74

Technical Indicators

Market Signals
Indicator
MYGN
VVX
Relative Strength Index (RSI) 38.37 43.12
Support Level $7.15 $54.15
Resistance Level $7.20 $55.94
Average True Range (ATR) 0.29 1.89
MACD -0.07 -0.10
Stochastic Oscillator 0.00 21.62

Price Performance

Historical Comparison
MYGN
VVX

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

About VVX V2X Inc.

V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.

Share on Social Networks: